Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.
The Tulsa, Oklahoma-based foundation announced it will increase its support by another $1 million, as VCNDD’s game-changing schizophrenia program approaches the point at which candidate drugs will be selected for testing in clinical trials. Two previous awards from the foundation have totaled $7.25 million since 2014.
Craig Lindsley, VCNDD director of Medicinal Chemistry and William K. Warren Jr. Professor of Medicine, said the center’s goal is to develop fundamentally new treatments born of deep basic science, not only for schizophrenia, but for multiple neuropsychiatric disorders.
The foundation’s support is essential to move drug-like molecules from laboratory and animal studies to the point where an investigational new drug (IND) application to test them in humans can be filed with the U.S. Food and Drug Administration (FDA), he said.
Sponsored Programs Administration (SPA) and CTTC partnered to help secure the support.
Read the complete article here.